We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
OBJECTIVES/SPECIFIC AIMS: The first aim of the study is to evaluate the accuracy of serum biomarkers of acute GVHD measured after four weeks of corticosteroid therapy to predict 6 month NRM. The second aim of this study is to compare the accuracy of the biomarker algorithm to that of clinical response to corticosteroids after four weeks. The third aim of the study is to develop a novel regression model that uses weekly biomarker measurements over the first month of corticosteroid therapy to predict 6 month NRM. METHODS/STUDY POPULATION:. Patients who received HCT at one of 22 IRB-approved centers and provided blood samples to the Mount Sinai Acute GVHD International Consortium (MAGIC) biorepository and developed GVHD between January 2008 to May 2018 are included in this study. Patients were divided by time into a training set (Jan 2008-Dec 2015, n=233) for model development and a validation set (Jan 2015-May 2018, n=357) to evaluate the predictive performance of the model. The later time of the validation set was chosen deliberately to model contemporaneous GVHD treatment practices. The size of each group was designed so that there would be roughly equal numbers of deaths in both groups. RESULTS/ANTICIPATED RESULTS:. Serum concentrations of GVHD biomarkers after one month of corticosteroid therapy were measured in the validation set, and the predicted probability of NRM (
$\hat{\rm p}$
) was computed according to the previously published algorithm:
$\log[-\log(1 - \hat{\rm p})]=-11.263 + 1.844({\rm logST}2)+ 0.577({\rm logREG}3\alpha)$
. The performance of the biomarker algorithm was evaluated by creating receiver operating characteristic (ROC) curves and calculating the area under the curve (AUC) in the validation set. The AUC of the biomarker algorithm was a significantly better predictor of 6 month NRM than clinical response to treatment after four weeks of corticosteroids (0.84 vs. 0.64, p<0.001), which is a clinically relevant improvement in accuracy. To evaluate serial biomarker monitoring, serum biomarker concentrations will be measured weekly at five time points from treatment initiation to one month after corticosteroid therapy. We will use these values in the training set to develop a regression model for 6 month NRM that accounts for repeated biomarker measurements. The performance of this model will be tested in the validation set and the accuracy of the serial biomarker measurements will be compared to the accuracy of measuring biomarkers at the single time point after four weeks of corticosteroid therapy. An AUC improvement of 0.05 would be considered clinically significant. DISCUSSION/SIGNIFICANCE OF IMPACT: Clinical response to treatment after four weeks has been the standard endpoint in GVHD interventional trials for decades. If biomarkers measured at the same time more accurately predict long term mortality, this study would provide the basis for a novel endpoint in GVHD trials and enable more accurate determination of effect size of experimental interventions. An accurate biomarker algorithm will prove useful in guiding immunosuppressive treatment decisions for patients with GVHD. Patients identified by the algorithm as low-risk may benefit from reduced-dose corticosteroid therapy, potentially reducing lethal opportunistic infections. Patients identified as high-risk will be candidates for more intensive immunosuppression or investigational therapies. This precision medicine approach tailors therapy to the individual patient’s biology.
We construct, over any CM field, compatible systems of
$l$
-adic Galois representations that appear in the cohomology of algebraic varieties and have (for all
$l$
) algebraic monodromy groups equal to the exceptional group of type
$E_{6}$
.
This second edition of The Cambridge Companion to George Eliot includes several new chapters, providing an essential introduction to all aspects of Eliot's life and writing. Accessible essays by some of the most distinguished scholars of Victorian literature provide lucid and original insights into the work of one of the most important writers of the nineteenth century, author most famously of Middlemarch, Adam Bede, The Mill on the Floss, and Daniel Deronda. From an introduction that traces her originality as a realist novelist, the book moves on to extensive considerations of each of Eliot's novels, her life and her publishing history. Chapters address the problems of money, philosophy, religion, politics, gender and science, as they are developed in her novels. With its supplementary materials, including a chronology and an extensive section of suggested readings, this Companion is an invaluable tool for scholars and students alike.
For those of us for whom “literary Darwinism,” which bases its “scientific” approach to literary criticism on evolutionary psychology, has seemed an intellectual disaster, but who continue to believe that it is important to incorporate science cooperatively into our study of literature; for those who are concerned about how art and literature matter in a world so troubled and dangerous; for those convinced Darwinians who find themselves skeptical about and uneasy with the mechanico-materialist version of Darwinism that Richard Dawkins and Daniel Dennett have made popular; for those who find that the science they credit is yet inadequately attentive to women's perspectives, Richard Prum's The Evolution of Beauty offers a potentially marvelous option. A distinguished ornithologist, Prum has undertaken an enormously ambitious project, whose implications run from evolutionary biology to aesthetics. From the perspective of a very unscientific literary guy and a wannabe birder, I slightly distrust my enthusiasm for the book. But Prum's arguments are creatively provocative and brilliantly argued, even when they get rather iffily hypothetical; his ornithological studies are intrinsically fascinating, even to nonbirders, and at the same time they have potentially transformative implications. What he has to say, even if his inferences can and should be challenged, deserves the most serious engagement.